drugset / Trial / NCT03381066
A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to compare the efficacy of intercalating chemotherapy (gefitinib and pemetrexed/cisplatin) and chemotherapy (navelbine/cisplatin) in completely resected NSCLC with common EGFR mutations.
Timeline
- Start
- 2018-04-10
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Gefitinib | Small molecule | 250 mg | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |
| Comparator | Vinorelbine | Small molecule | 25 mg/m2 | — |
Indications
No indication recorded.